Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
22.41(c) 22.6(c) 22.26(c) 22.21(c) 21.975 Last
299 509 337 668 534 094 411 705 145 620 Volume
-1.28% +0.85% -1.50% -0.22% -1.06% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 83,4 M - -
Net income 2021 -125 M - -
Net cash position 2021 129 M - -
P/E ratio 2021 -13,7x
Yield 2021 -
Sales 2022 52,9 M - -
Net income 2022 -158 M - -
Net cash position 2022 92,2 M - -
P/E ratio 2022 -11,2x
Yield 2022 -
Capitalization 1 718 M 1 718 M -
EV / Sales 2021 19,0x
EV / Sales 2022 30,7x
Nbr of Employees 210
Free-Float 70,5%
More Financials
Company
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The CompanyÔÇÖs product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic... 
More about the company
Ratings of NGM Biopharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about NGM BIOPHARMACEUTICALS, INC.
09/17NGM BIOPHARMACEUTICALS : BMO Capital Raises Price Target on NGM Biopharmaceuticals to $35 ..
MT
09/16NGM BIOPHARMACEUTICALS : Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose E..
AQ
09/16NGM Biopharmaceuticals, Inc. Presents Preliminary Findings from Ongoing Phase 1A/1B Dos..
CI
09/13NGM BIOPHARMACEUTICALS : Stock Climbs After Raymond James Upgrade
MT
09/13NGM BIOPHARMACEUTICALS : Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy From ..
MT
09/07NGM BIOPHARMACEUTICALS : B. Riley Raises NGM Biopharmaceuticals' PT to $35 from $32 Ahead ..
MT
08/23NGM BIOPHARMACEUTICALS : Developing NGM831 to Treat Cancer
MT
08/23NGM BIOPHARMACEUTICALS : Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3..
AQ
08/23NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, a..
CI
08/09NGM BIOPHARMACEUTICALS : BMO Capital Adjusts NGM Biopharmaceuticals' Price Target to $29 F..
MT
08/09NGM BIOPHARMACEUTICALS : Goldman Sachs Adjusts NGM Biopharmaceuticals' Price Target to $25..
MT
08/09NGM BIOPHARMACEUTICALS : Cowen Adjusts NGM Biopharmaceuticals' Price Target to $32 From $2..
MT
08/06NGM BIOPHARMACEUTICALS : Piper Sandler Adjusts Price Target on NGM Biopharmaceuticals to $..
MT
08/05NGM BIOPHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/05NGM BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News in other languages on NGM BIOPHARMACEUTICALS, INC.
09/13L'action de NGM Biopharmaceuticals grimpe après la mise à niveau de Raymond James
2020NGM BIOPHARMACEUTICALS, INC. : des résultats encourageants
More news
Analyst Recommendations on NGM BIOPHARMACEUTICALS, INC.
More recommendations
Chart NGM BIOPHARMACEUTICALS, INC.
Duration : Period :
NGM Biopharmaceuticals, Inc. Technical Analysis Chart | NGM | US62921N1054 | MarketScreener
Technical analysis trends NGM BIOPHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 22,21 $
Average target price 34,83 $
Spread / Average Target 56,8%
EPS Revisions
Managers and Directors
David J. Woodhouse Chief Executive Officer & Director
Siobhan Nolan Mangini CFO & Principal Accounting Officer
William J. Rieflin Executive Chairman
Hui Tian Vice President-Research
Marc Learned Vice President-Research Operations
Sector and Competitors
1st jan.Capi. (M$)
NGM BIOPHARMACEUTICALS, INC.-26.69%1 718
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582